Patent · US Active

Galactoside inhibitor of galectins

US11447517B2 · kind B2 · utility

1Cited by
0References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 15, 2019
Grant dateSep 20, 2022
Priority date
Expiry dateNov 15, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07H19/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.